User:Mr. Ibrahem/Tafamidis

Tafamidis, sold under the brand names Vyndaqel among others, is a medication used to treat transthyretin-mediated amyloidosis. It is taken by mouth. It can be stopped after liver transplantation.

Common side effects include abdominal pain, diarrhea, and infection. Use during pregnancy is believed to harm the baby. It works by stabilizing the protein transthyretin, thus decreasing the formulation amyloids.

Tafamidis was approved for medical use in Europe in 2011 and the United States in 2019. In the United Kingdom a month of 20 mg per day costs the NHS about £10,700 as of 2021. This amount in the United States costs about 4,900 USD.